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␤ 1 -, ␤ 2 -, and ␤ 3 -receptors, some of which have entered clinical medicine. Selective agonists for the ␤ 2 -adrenergic receptor play an important role in asthma therapy, whereas ␤ 1 -receptor antagonists are first-line medication for patients with hypertension, coronary heart disease, or chronic heart failure (8, 20, 50) . For ␣ 1 -receptors, subtype-selective ligands that can diminish the symptoms of benign prostate hyperplasia without causing hypotension have just entered clinical therapy (33) . Despite the fact that ␣ 2 -adrenergic receptors serve a number of physiological functions in vivo and have great therapeutic potential, no sufficiently subtype-selective ligands are clinically available yet. Despite this fact, non-subtype-selective ␣ 2 -receptor agonists like clonidine, medetomidine, and brimonidine are being used to treat patients with hypertension, glaucoma, tumor pain, postoperative pain, and shivering or to block the symptoms of sympathetic overactivity during drug withdrawal (66) . Unfortunately, the fields of therapeutic application and unwanted side effects are overlapping, e.g., ␣ 2 -receptor-mediated sedation is an important problem for treatment of hypertension. Severe side effects are one reason why ␣ 2 -receptor agonists are only second-line antihypertensive agents. It is tempting to speculate that ␣ 2 -receptor-mediated therapy could be greatly improved and advanced if receptor subtype-selective ligands were available. However, before developing specific ligands, the therapeutic targets have to be identified. Recently, transgenic and genetargeted mouse models have added considerable information about individual adrenergic receptor subtypes (15, 25, 37, 39, 53, 54) . This review focuses on the specific functions of the three ␣ 2 -adrenergic receptor subtypes in mouse models carrying targeted deletions in the genes encoding for ␣ 2 -receptors.
␣2-ADRENERGIC RECEPTOR GENES
So far, three distinct genes have been identified from several species that encode for separate subtypes of ␣ 2 -adrenergic receptors (11) . From these genes, three ␣ 2 -receptors are synthesized, termed ␣ 2A , ␣ 2B , and ␣ 2C . The pharmacological ligand binding characteristics of the ␣ 2A -subtype differ significantly between different species, thus giving rise to the pharmacological subtypes ␣ 2A in humans, rabbits, and pigs and ␣ 2D in rats, mice, and guinea pig (11) . This species variation is at least in part due to a single amino acid variation in the fifth transmembrane domain of the ␣ 2A -receptor that renders this receptor less sensitive to yohimbine binding (34) .
GENE-TARGETED MICE LACKING INDIVIDUAL ␣2-RECEPTOR SUBTYPES
Several mouse lines have been established by gene targeting that do not express functional ␣ 2 -adrenergic receptors (2, 35, 36) . All of these mice developed apparently normally, although mice lacking ␣ 2B -adrenergic receptors were not born at the expected Mendelian ratios, indicating that this receptor may play a role during embryonic development (13, 35) .
In addition, a point mutation has been introduced into the ␣ 2A -receptor gene (␣ 2 -D79N) to evaluate the physiological role of separate intracellular signaling pathways of this receptor in vivo (38) . The D79N mutation substitutes asparagine for an aspartate residue at position 79, which is predicted to lie within the second transmembrane region of the ␣ 2A -receptor and is highly conserved among G protein-coupled receptors. In vitro, the ␣ 2A -D79N receptor has been shown to be deficient in coupling to K ϩ channel activation (76) . However, in vivo this point mutation was found to be deficient in K ϩ current activation and Ca 2ϩ channel inhibition (32) . Surprisingly, the density of ␣ 2A -D79N receptors in the mouse brain was decreased to ϳ20% of the normal level (38) . Thus, in most (but not all) functional tests, the ␣ 2A -D79N receptor had characteristics resembling a functional "knockout" of the ␣ 2A -receptor (40) . One important exception was the observation that the presynaptic inhibitory function of the ␣ 2A -D79N receptor was normal or only slightly blunted in intact tissues (2) . Most likely, the decreased expression of ␣ 2A -D79N receptors in vivo rather than a selective defect in receptor signaling seems to be important for the "functional knockout." At the presynaptic side, a high number of spare receptors is characteristic for ␣ 2 -receptor function, i.e., activation of very few ␣ 2 -receptors results in maximal presynaptic inhibition of transmitter release (1) . Thus the reduced number of presynaptic ␣ 2A -D79N receptors may still be sufficient for presynaptic control, whereas the decreased receptor density may compromise receptor signal transduction at other sites with a smaller receptor reserve.
WHICH ␣2-RECEPTOR SUBTYPE IS THE PRESYNAPTIC REGULATOR?
␣ 2 -Adrenergic receptors were initially characterized as presynaptic receptors that serve as parts of a negative feedback loop to regulate the release of norepinephrine (71) . Soon it was shown that ␣ 2 -receptors are not restricted to presynaptic locations but also have postsynaptic functions (Fig. 1A) . With the use of an array of pharmacological antagonists, the ␣ 2A -receptor was predicted to be the major inhibitory presynaptic receptor regulating release of norepinephrine from sympathetic neurons as part of a feedback loop (82) . However, in some tissues, the ␣ 2C -receptors were considered to be in the inhibitory presynaptic receptor (55) .
With the genetic deletion of individual ␣ 2 -receptor genes in mice, this classification of the presynaptic autoreceptor subtype was challenged. In mice lacking the ␣ 2A -subtype, presynaptic feedback regulation was severely impaired but not abolished, indicating that indeed the ␣ 2A -receptor is the major autoreceptor in sympathetic neurons (Fig. 1A) (2, 26) . Most surprisingly, the ␣ 2C -receptor turned out to function as an additional presynaptic regulator in all central and peripheral nervous tissues investigated (Fig. 1A) (2, 9, 26, 70, 79, 80) . However, the relative contributions of ␣ 2A -and ␣ 2C -receptors differed between central and peripheral nerves, with the ␣ 2C -receptor being more prominent in sympathetic nerve endings than in central adrenergic neurons. ␣ 2A -and ␣ 2C -receptors differ in their time course of expression after birth (65) . While ␣ 2A -mediated autoinhibition of neurotransmitter release is already operative immediately after birth, the ␣ 2C -receptor function is established later in mice (65) .
Furthermore, the ␣ 2 -autoreceptor subtypes could be distinguished functionally: ␣ 2A -receptors inhibited transmitter release significantly faster and at higher action potential frequencies than the ␣ 2C -receptors (Fig. 1B) (9, 26, 62) . When ␣ 2A -and ␣ 2C -receptors were stably expressed together with N-type Ca 2ϩ channels or with G protein-coupled inwardly rectifying K ϩ (GIRK) channels, no differences in the activation kinetics of these two receptor subtypes were detected at identical levels of receptor expression (10) . However, when receptor GIRK channel deactivation after removal of norepinephrine was followed, the ␣ 2C -receptor was found to be active for a significantly longer time than the ␣ 2A -subtype irrespective of the level of receptor expression. This difference in ␣ 2 -receptor deactivation kinetics could be explained by the higher affinity of norepinephrine for the ␣ 2C -than for the ␣ 2A -receptor subtype (10) . This property makes the ␣ 2C -receptor particularly suited to control neurotransmitter release at low action potential frequencies ( Fig. 1) (26) . In contrast, the ␣ 2A -receptor seems to operate primarily at high stimulation frequencies in sympathetic nerves and may thus be responsible for controlling norepinephrine release during maximal sympathetic activation.
␣ 2 -Adrenergic receptors not only inhibit release of their own neurotransmitters (autoreceptors) but can also regulate the exocytosis of a number of other neurotransmitters in the central and peripheral nervous system. In the brain, ␣ 2A -and ␣ 2C -receptors can inhibit dopamine release in basal ganglia (9) as well as serotonin secretion in mouse hippocampal or brain cortex slices (61) . In contrast, the inhibitory effect of ␣ 2 -agonists on gastrointestinal motility was mediated solely by the ␣ 2A -subtype (63) .
Part of the functional differences between ␣ 2A -and ␣ 2C -receptors may be explained by their distinct subcellular localization patterns ( Fig. 2) (14, 47, 86, 87) . In cultured sympathetic neurons from newborn mice, functional presynaptic ␣ 2 -receptors develop to inhibit voltage-dependent Ca 2ϩ channels and norepinephrine release (77, 78) . In sympathetic neurons, only the ␣ 2A -subtype but not the ␣ 2C -receptor contributed to inhibition of neurotransmitter release (81) . Remarkably, in- Fig. 1 . Presynaptic ␣2-adrenergic receptor subtypes. A: in sympathetic or central adrenergic nerves, ␣2A-and ␣2C-receptors operate as inhibitory autoreceptors to control neurotransmitter release. ␣2B-Receptors are located on postsynaptic cells to mediate the effects of catecholamines released from sympathetic nerves, e.g., vasoconstriction. B: presynaptic ␣2A-and ␣2C-receptors can be distinguished functionally. In intact tissue slices from mouse heart atria, ␣2A-receptors inhibit norepinephrine release from sympathetic nerves primarily at high stimulation frequencies, whereas the ␣2C-receptor can also operate at very low frequencies to control basal norepinephrine release. WT, wild type. Data adapted from Ref. 26 . When expressed in rat1 fibroblasts, ␣2A-and ␣2B-receptors are targeted to the plasma membrane (immunofluorescence images). On stimulation with agonist, only ␣2B-receptors are reversibly internalized into endosomes. ␣2C-Receptors are primarily localized in an intracellular membrane compartment, from where the ␣2C-receptors can be translocated to the cell surface after exposure to cold temperature (29) . Bottom: murine ␣2-receptor subtypes after transient transfection into rat1 fibroblasts as described previously (14) . Arrows point to ␣2-receptors residing in the plasma membrane; arrowhead marks ␣2C-receptors in an intracellular compartment.
hibition of Ca 2ϩ channels located on neuronal cell bodies and dendrites was mediated by both ␣ 2A -and ␣ 2C -receptors. Thus ␣ 2C -receptors in neurons may require a specific itinerary to guide their expression to axonal termini.
BLOOD PRESSURE REGULATION
␣ 2 -Receptors are involved in the control of blood pressure homeostasis at a number of locations (Fig. 3) . Nonselective activation of ␣ 2 -receptors usually leads to a biphasic blood pressure response: after a short hypertensive phase that is more pronounced after rapid intravenous injection, arterial pressure falls below the baseline. After oral application of ␣ 2 -agonists, the hypotensive action prevails and is being used to treat elevated blood pressure in hypertensive patients. Interestingly, the two phases of the pressure response are mediated by two different ␣ 2 -receptor subtypes in vivo: ␣ 2B -receptors are responsible for the initial hypertensive phase, whereas the long-lasting hypotension is mediated by ␣ 2A -receptors (2, 35, 38) . Thus the ␣ 2A -receptor is a therapeutic target for subtype-selective antihypertensive agents. The blockade of ␣ 2 -receptors may be of therapeutic benefit in patients with atherosclerotic coronary arteries (3), whereas it is still unknown which ␣ 2 -receptor subtype is responsible for the vasoconstriction in humans. An insertion/deletion polymorphism with decreased receptor desensitization of the ␣ 2B -receptor subtype is associated with an increased risk for acute coronary events (69) .
Some evidence indicates that ␣ 2A -receptors also participate to a smaller degree in the vasoconstrictor action of ␣ 2 -agonists in mice (38) . Bolus injection of norepinephrine caused transient hypertension in wildtype mice and in ␣ 2B -and ␣ 2C -deficient mice but not in mice lacking the ␣ 2A -receptor (16) . Vascular ␣ 2 -receptor subtypes may be differentially distributed between vascular beds. When ␣ 2 -agonists were injected into the carotid artery, most of the hypertensive response to ␣ 2 -activation was mediated by the ␣ 2B -receptor (35) , whereas injection into the femoral artery showed a blunted hypertensive effect in mice with the ␣ 2A -D79N receptor (38) . In some arteries, ␣ 2 -mediated vasoconstriction may even predominate over ␣ 1 -receptor-induced contraction, and decreased ␣-receptor responsiveness may contribute to elevated blood flood in tissue inflammation, e.g., arthritis (45) .
In addition to its role as a vasoconstrictor, the ␣ 2B -receptor seems to be required for the development of salt-sensitive hypertension (Fig. 3) (22, 41-43 ). Nephrectomy followed by Na ϩ loading has been established as a model of hypertension in mice (22) . In this system, the development of hypertension depends on increased vasopressin release and sympathetic activation (21) . Bilateral nephrectomy and saline infusion raised blood pressure in wild-type and in ␣ 2A -and ␣ 2C -receptor-deficient mice. However, in ␣ 2B -deficient animals a small fall in arterial pressure was observed (41) . Recent experiments with ␣ 2B -antisense oligonucleotide injection into the lateral brain ventricle suggest that a central ␣ 2B -adrenergic receptor is necessary for induction of salt-dependent hypertension (31) .
Under certain conditions, even the ␣ 2C -receptor subtype may contribute to vascular regulation: when kept below 37°C for a while, cutaneous arteries of the mouse tail show an ␣ 2C -receptor-dependent vasoconstriction that could not be observed when the vessel segments were incubated at body temperature (12) . This finding may be of great therapeutic interest for the treatment of Raynaud's disease. Patients with Raynaud's phenomenon suffer from severe periods of vasoconstriction of their fingers and toes that are usually triggered by exposure to cold. Treatment of these patients with ␣ 2 -adrenergic antagonists diminished the vasoconstriction (19) . Interestingly, silent ␣ 2C -receptors may be translocated from an intracellular receptor pool to the cell surface on cooling (Fig. 2) (29) . This phenomenon has been observed in human embryonic kidney (HEK-293) cells transfected with recombinant ␣ 2C -receptors: cooling of cells to 28°C evoked a redistribution of ␣ 2C -receptors from the Golgi apparatus to the plasma membrane within 1 h (29). Thus inhibition of ␣ 2C -receptors may prove an effective treatment for Raynaud's phenomenon.
In addition to these vascular and central neuronal mechanisms, renal ␣ 2 -receptors may be involved in the Fig. 3 . Integrative regulation of blood pressure by different ␣2-adrenergic receptor subtypes. Activation of ␣2A-receptors leads to a decrease in blood pressure by inhibiting central sympathetic outflow as well as norepinephrine release from sympathetic nerves (2, 38) . ␣2B-Receptors may counteract this effect by causing direct vasoconstriction and salt-induced hypertension (22, 35) . ␣2C-Receptors participate in ␣2-mediated vasoconstriction after exposure to cold temperature (12) . long-term regulation of blood pressure and fluid and electrolyte homeostasis (48, 49) . Activation of renal vascular ␣ 2B -receptors may lead to an increase in medullary NO production and thus counteract the vasoconstrictor effects of norepinephrine in the renal medulla (90) . Via this mechanism, ␣ 2B -receptors may be essential in the regulation of renal medullary blood flow and oxygen supply. ANALGESIA ␣ 2 -Agonists are potent analgesics, and they can potentiate the analgesic effect of opioids (75, 85, 88) . Recent data indicate that all three ␣ 2 -receptor subtypes are involved in the regulation of pain perception in the mouse (Fig. 4) .
The ␣ 2A -receptor mediates the antinociception induced by systemically applied ␣ 2 -agonists, including clonidine and dexmedetomidine (18, 74) . Compared with control mice, ␣ 2 -agonists were completely ineffective as an antinociceptive agent in the tail immersion or substance P test in ␣ 2A -D79N mice (27) . The ␣ 2A -D79N mutation also blocked the synergy seen in wildtype mice between ␣ 2 -agonists and delta-opioid agonists (74) . Interestingly, ␣ 2A -receptor-deficient mice showed a reduced antinociceptive effect to isoflurane (30) . However, not all ␣ 2 -receptor agonists required functional ␣ 2A -receptors for their antinociceptive effect (Fig. 4) . The imidazoline/␣ 2 -receptor ligand moxonidine caused spinal antinociception that was at least partially dependent on ␣ 2C -receptors (17) . Surprisingly, nitrous oxide, which is used as a potent inhalative analgesic during anesthesia, requires the ␣ 2B -subtype for its antinociceptive effect (Fig. 4) (23, 60) . Supraspinal opioid receptors and spinal ␣ 2B -receptors are involved in the analgesic pathway for nitrous oxide. Activation of endorphin release in the periaqueductal gray by nitrous oxide stimulates a descending noradrenergic pathway that releases norepinephrine onto ␣ 2B -receptors in the dorsal horn of the spinal cord (89) . In mice lacking ␣ 2B -receptors, the analgesic effect of nitrous oxide was completely abolished (60) .
SEDATION
␣ 2 -Agonists are used in the postoperative phase or in intensive care as sedative, hypnotic, and analgesic agents (44, 66) . The sedative effects of ␣ 2 -agonists in mice are solely mediated by the ␣ 2A -receptor subtype (32) . ␣ 2A -D79N mice showed no sedative response to the ␣ 2 -agonist dexmedetomidine (32) . In contrast, mice lacking the ␣ 2B -or ␣ 2C -receptors did not differ in their sedative response from wild-type control mice (27, 59) . Similarly, the anesthetic-sparing effect of ␣ 2 -agonists was completely abolished in ␣ 2A -D79N mice (32) .
The hypnotic effect of ␣ 2 -agonists is most likely mediated in the locus ceruleus. Neurons of the locus ceruleus express ␣ 2A -adrenergic receptors at very high density (84) . Furthermore, ␣ 2A -antisense oligonucleotide injection into the locus ceruleus in rats attenuated the sedative effects of exogenous ␣ 2 -agonists (46) .
BEHAVIOR
Because of their widespread distribution in the central nervous system, ␣ 2 -receptors affect a number of behavioral functions (5, 56, 57, 67) . In particular, the ␣ 2C -receptor subtype has been demonstrated to inhibit the processing of sensory information in the central nervous system of the mouse (for a recent review, see Ref. 64 ). Activation of ␣ 2 -receptors also resulted in locomotor inhibition. While direct activation of ␣ 2 -receptors by dexmedetomidine did not alter spontaneous motor activity in ␣ 2C -receptor-deficient mice (59), D-amphetamine stimulated locomotor activity to a greater extent in ␣ 2C -deficient mice than in wild-type mice (58) .
Mice overexpressing ␣ 2C -receptors were impaired in spatial and nonspatial water maze tests, and an ␣ 2 - Fig. 4 . Three ␣2-adrenergic receptor subtypes are involved in the control of pain perception in mice. A: schematic representation of ␣2-receptor subtypes controlling spinal nociception. B: distribution of ␣2-receptors in the mouse spinal cord by autoradiography with a non-subtype-selective ␣2-receptor antagonist (9). In the spinal cord, the highest density of ␣2-adrenergic receptors was observed in the superficial layers of the dorsal horns (B, arrows). Here, all 3 ␣2-receptor subtypes control incoming nociceptive impulses: ␣2A-receptors are required for the analgesic effect of systemically applied ␣2-agonists, spinal ␣2C-receptors contribute to the moxonidine-mediated analgesia, and ␣2B-receptors are required for the spinal antinociceptive effect of nitrous oxide. See text for references. The autoradiogram shown in B was kindly provided by K. Hadamek, Wü rzburg, Germany.
antagonist fully reversed the water maze escape defect in these mice (4-6). The ␣ 2 -agonist dexmedetomidine increased swimming distance more effectively in wildtype mice than in ␣ 2C -receptor-deficient mice (4). Activation of ␣ 2C -receptors disrupts execution of spatial and nonspatial search patterns, whereas stimulation of ␣ 2A -and/or ␣ 2B -receptors may actually improve spatial working memory in mice (7) . It may be concluded that novel agonists devoid of ␣ 2C -receptor affinity can modulate cognition more favorably than non-subtypeselective drugs.
Altered startle reactivity and attenuation of the inhibition of the startle reflex by an acoustic prepulse have been observed in schizophrenia, and disrupted prepulse inhibition has frequently been used as an animal model for drug antipsychotic drug development. Interestingly, ␣ 2C -receptor-deficient mice had enhanced startle responses, diminished prepulse inhibition, and shortened attack latency in the isolationaggression test (57) . Thus drugs acting via the ␣ 2C -receptor may have therapeutic value in disorders associated with enhanced startle responses and sensorimotor gating deficits, such as schizophrenia, attention deficit disorder, posttraumatic stress disorder, and drug withdrawal. In addition to the ␣ 2C -subtype, the ␣ 2A -receptor has an important role in modulating behavioral functions. Experiments using gene-targeted mice indicate that the ␣ 2A -receptor may play a protective role in some forms of depression and anxiety, and this receptor may mediate part of the antidepressant effects of imipramine (67) . Thus ␣ 2A -and ␣ 2C -receptors complement each other to integrate central nervous system function and behavior.
OTHER PHYSIOLOGICAL FUNCTIONS AND PHARMACOLOGICAL TARGETS
␣ 2 -Receptors are involved in the regulation of body temperature as well as seizure threshold. Activation of central ␣ 2A -receptors causes a powerful antiepileptogenic effect in mice (28) . Two receptor subtypes, ␣ 2A and ␣ 2C , may be involved in the hypothermic action of ␣ 2 -agonists (27, 59) . Another important function of ␣ 2 -agonists is their inhibitory effect on intraocular pressure. The ␣ 2 -agonists apraclonidine and brimonidine are currently being used to lower intraocular pressure in patients with glaucoma (52, 68) . In adipose tissue, ␣ 2 -receptors inhibit lipolysis (72, 73) and ␣ 2 -receptors are potential targets for the treatment of obesity. Mice expressing human ␣ 2 -receptors in fat tissue in vivo, in the absence of ␤ 3 -adrenergic receptors, developed high-fat diet-induced obesity (83) . However, the precise role of individual ␣ 2 -receptor subtypes in the control of lipolysis is unknown at present.
CONCLUSIONS
Genetic deletion of ␣ 2 -adrenergic receptor subtype genes in mice has greatly enhanced our understanding of the physiological functions and therapeutic potential of individual ␣ 2 -receptor subtypes. ␣ 2 -Adrenergic receptors are important regulators of sympathetic tone, neurotransmitter release, blood pressure, and intraocular pressure. ␣ 2 -Receptor activation causes sedation and potent analgesia. Further potential therapeutic functions may be unraveled with the help of mouse models with deleted ␣ 2 -receptor genes. Before these genetic animal models were available, it was hypothesized that each biological function of ␣ 2 -receptors would be mediated by one receptor subtype. Thus it was reasonable to assume that novel subtype-specific pharmacological agonists or antagonists would be of great therapeutic value because of their reduced potential for ␣ 2 -receptor-mediated side effects. However, with more and more studies of the ␣ 2 -receptor physiology in gene-targeted mice being published, the situation became more complicated than initially anticipated. Indeed, only a few biological functions of ␣ 2 -receptors were found to be mediated by one single ␣ 2 -adrenergic receptor subtype. Examples are the hypotension or sedation caused by ␣ 2A -receptor activation.
For other ␣ 2 -receptor-mediated functions, two different strategies seem to have emerged to regulate adrenergic signal transduction: some biological functions are controlled by two counteracting ␣ 2 -receptor subtypes, e.g., ␣ 2A -receptors decrease sympathetic outflow and blood pressure, whereas the ␣ 2B -subtype increases blood pressure by direct vasoconstriction. In contrast, the inhibitory presynaptic feedback loop that tightly regulates neurotransmitter release from adrenergic nerves requires two receptor subtypes, ␣ 2A and ␣ 2C , with similar but complementary effects. Similarly, pain perception is controlled at several levels of by one of the three ␣ 2 -receptor subtypes.
The fact that more than one receptor subtype may be involved in regulating one particular physiological function does not limit the therapeutic potential of novel subtype-selective drugs for ␣ 2 -adrenergic receptors. However, it emphasizes that knowledge of the spectrum of in vivo biological effects is mandatory before making precise predictions about the in vivo effects of subtype-specific drugs. For treatment of hypertension, a selective ␣ 2A -receptor agonist without affinity for the ␣ 2B -receptor might be advantageous. As ␣ 2B -receptors counteract the hypotensive effect of ␣ 2A -receptor activation, a selective ␣ 2A -agonist could be given at a lower dose to achieve similar blood pressure lowering with reduced sedative side effects. In addition, a combination of agonistic and antagonistic properties may become desirable, for instance, for antihypertensives, e.g., ␣ 2A -agonist and ␣ 2B -antagonist. The primary target for ␣ 2 -mediated pain modulation would be the ␣ 2B -receptor. As illustrated by the potent analgesic effect of nitrous oxide, ␣ 2B -receptor activation might be a very promising analgesic strategy. Whether ␣ 2C -receptors are equally effective in inhibiting pain pathways in the spinal cord has to be tested in future studies (17) . The main advantage of ␣ 2B -or ␣ 2C -receptor-specific agonists for antinociception would be their lack of sedative side effects compared with nonselective ␣ 2 -agonists that also stimulate ␣ 2A -receptors. In addition, they would not cause respiratory depression and addiction, which are two major problems associated with opioid therapy. In anesthesia and intensive care, the availability of pairs of subtype-selective agonists and antagonists might be of great benefit (66) . ␣ 2A -Receptor-mediated sedation that can be rapidly reversed by a selective ␣ 2 -antagonist may be used in future human anesthesia (as it is already being used with non-subtype-selective agonists/antagonists in veterinary anesthesia). Finally, mice lacking all ␣ 2 -receptor subtypes will also be essential tools to determine the function of imidazoline receptors and the potential of future imidazoline receptor drugs (24, 51) .
Further investigation of the specific function of ␣ 2 -subtypes will greatly enhance our understanding of the relevance of closely related receptor proteins and point out novel therapeutic strategies for subtype-selective drug development.
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